CRF Health, the leading global provider of eCOA solutions for the life sciences industry, announces agreements with two top tier pharmaceutical companies to support drug development initiatives in women's health. Selected for three high priority oncology studies for three new molecular entities, CRF Health's TrialMax® platform will support data capture for quality of life issues during the post-progression phase.
The three large scale studies into ovarian cancer and breast cancer will encompass 542 sites, 23 countries and almost 2,000 female trial participants, across the U.S, Europe and Asia Pacific. For post-progression studies, the move from paper-based data collection to electronic methods is vital to providing unobtrusive and convenient care for patients too ill to visit study sites. CRF Health's TrialMax Touch® handheld patient diary will be used to support patients during these critical multi-year research initiatives, driving the collection of data that enhances these sponsors' data packages.
"We are pleased to have been selected as a partner of choice for these important drug development initiatives in women's oncology", said John Blakeley, Chief Business Officer at CRF Health. "With experience supporting more than 90 oncology studies, we are at the forefront of electronic data collection in this area. Our solution has been selected due to its unique design which allows us to collect data from patients in sensitive circumstances. We have given careful consideration to design a system with a more holistic approach to data capture in these uniquely challenging studies, ensuring ease-of-use for patients while making certain care remains at the center of clinical trials."
For further information on CRF Health, please visit www.crfhealth.com
About CRF Health
CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 650 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention.
CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.